Showing results (211-220 of 367) with videos related to
Sort By:
Pageof 37
Protein Engineering, Design & Selection : PEDS|September 1, 2016
TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populationsRaffaella Castoldi, Jürgen Schanzer, Christian Panke, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screenJasper Mullenders, Wolfgang von der Saal, Miranda M W van Dongen, et al.Nature Communications|February 24, 2021
Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulationEnrique J Arenas, Alex Martínez-Sabadell, Irene Rius Ruiz, et al.British Journal of Haematology|October 17, 2015
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALLAradhana Awasthi, Janet Ayello, Carmella Van de Ven, et al.Journal of Alzheimer'S Disease : JAD|July 1, 2019
TSPO Ligands Boost Mitochondrial Function and Pregnenolone SynthesisImane Lejri, Amandine Grimm, François Hallé, et al.Arthritis & Rheumatology (Hoboken, N.J.)|December 5, 2020
The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus ModelAnthony D Marinov, Haowei Wang, Sheldon I Bastacky, et al.Protein Engineering, Design & Selection : PEDS|September 11, 2019
P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutationDiana Darowski, Christian Jost, Kay Stubenrauch, et al.The AAPS Journal|December 4, 2021
A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data AnalysisArthur Van De Vyver, Miro Eigenmann, Meric Ovacik, et al.The AAPS Journal|October 7, 2022
Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1Javier Sánchez, Valeria Nicolini, Linda Fahrni, et al.Frontiers in Cell and Developmental Biology|November 29, 2023
Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignanciesEster Fagnano, Swati Pendharkar, Madyson Colton, et al.Pageof 37